



AAO23: Allergic Rhinitis: Intranasal Corticosteroids or Oral Antihistamines

High Priority Status: No; N/A
NQF Number: N/A

Percentage of patients age 2 years and older with allergic rhinitis who are offered intranasal corticosteroids (INS) or non-sedating oral antihistamines.

Denominator:
All patients age 2 years and older with a diagnosis of allergic rhinitis.

Denominator Exclusions:
None

Denominator Exceptions:

- Patients with an allergy to oral antihistamines or intranasal corticosteroids.
- Patients with prostate cancer or benign prostatic hypertrophy as these patients may be intolerant of medications.
- Patients with a history of epistaxis due to intranasal steroid use.
- Patients with glaucoma.
- Patient refusal.

Numerator:
Patients who are taking intranasal steroids (INS) or non-sedating oral antihistamines. A prescription for or medication reconciliation of over-the-counter medications can be used to identify patients taking medications.

Numerator Exclusions:
None

Measure Classifications:
Measure Type: Process
National Quality Strategy (NQS) domain: Effective Clinical Care
Meaningful Measures Area: Medication Management
Care Setting(s): Ambulatory Care: Clinician Office/Clinic
Includes Telehealth: Yes
Number of Performance Rates: 1
Inverse measure: No
Continuous measure: No
Proportional measure: Yes
Ratio measure: No
Risk-adjusted measure: No


© 2022 American Academy of Otolaryngology–Head and Neck Surgery Foundation. All rights reserved.
Limited proprietary coding is contained in the measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The measures, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g. use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the measures for commercial gain, or incorporation of the measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the measures require a license agreement between the user and the American Academy of Otolaryngology – Head and Neck Surgery Foundation.

The measure is not a clinical guideline, does not establish a standard of medical care, and has not been tested for all potential applications. The measure and specifications are provided “as is” without warranty of any kind. Neither the American Academy of Otolaryngology – Head and Neck Surgery Foundation (AAO-HNSF), nor its members shall be responsible for any use of the measure. The AAO-HNSF and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications.

INITIAL PATIENT POPULATION (IPP)

MEASURE DESCRIPTION

Percentage of patients with allergic rhinitis who are offered intranasal corticosteroids (INS) or non-sedating oral antihistamines.



DENOMINATOR


***Denominator Exceptions:**

MEDICAL REASONS:

- Allergy to oral antihistamines or intranasal corticosteroids
- Prostate cancer or benign prostatic hypertrophy
- History of epistaxis due to intranasal steroids use
- Glaucoma

PATIENT REASON

- Refusal of intranasal corticosteroids or non-sedating oral antihistamines



NUMERATOR

